Navigation Links
Yongye Biotechnology International to Expand its Network of Branded Stores

BEIJING, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), a leading developer, producer and distributor of nutrients for plants and animals in the People's Republic of China, today announced plans to expand its network of branded stores from 775 to over 1,125 stores.

In the quarter ended December 31, 2008, the Company added 350 stores to its trial process through which stores are evaluated according to region-specific performance goals. A storeowner's ability to understand the Company's products, provide pre-sales service and post-sales support, and ability to generate revenue by selling "Shengmingsu" brand products are assessed during this trial process which lasts two to four quarters. The Company's intent is to brand all of the stores which successfully complete this trial process. Additionally, the Company plans to continue to add more stores in the first quarter of 2009 to bring its total number of Yongye branded stores to over 1,125 by the end of the quarter. The Company anticipates having 2,000 Yongye branded stores by the end of 2009.

The Company does not own any of its branded stores. Yongye works with distributors to target existing, independent agricultural stores which it believes meets its national branding criteria and then enters into agreements with storeowners through which the Company provides training about its products to storeowners and a computer to each store which contains educational and promotional information about the use of its products. Before becoming a Yongye branded store, stores are often physically cleaned and upgraded to meet the Company's national standards. Once a store becomes a Yongye branded store, Yongye's name is prominently displayed in front of the store, and its products are featured as headline products throughout the store through the use of various visual identity items. Storeowners receive direct marketing and product support from Yongye's service professionals and the opportunity to sell a high quality nationally marketed product.

A network of independent distributors sells Yongye's products to the branded stores, which are located in 10 provinces. These distributors have the important task of attaching storeowners of newly branded stores to the Company's overall sales network by providing them with the training and support needed to link the Company to its end users. Underscoring the importance of the independent distributors to its sales model, the Company plans to increase and strengthen its distribution network throughout 2009.

"Expanding our distribution channels and network of branded stores is critical for us to keep pace with market demand for our products. Our easily scalable 'community-based' branded store sales model is unique in our industry and has allowed us to increase sales faster than if we developed our own corporate stores," said Mr. Zishen Wu, Chairman and CEO of Yongye. "We recently expanded our production facilities and will be able to support additional stores and meet demand for our "Shengmingsu" plant and animal nutrient products. Looking at the stores currently going through the trial process, we see the largest number of new stores in Hebei province, while our fastest growth is in Shandong province."

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products which increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Forward Looking Statements

Certain statements set forth in this press release constitute "Forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: the effects of the current drought affecting many regions of the PRC, the global financial crisis, patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

    For more information, please contact:

    Yongye Biotechnology International, Inc.
     Mr. Larry Gilmore, VP of Corporate Strategy
     Phone: +86-8232-8866 x8880

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone:    +1-646-213-1915 (New York)
     Web site:

SOURCE Yongye Biotechnology International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
2. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Yongye Biotechnology International Raises $9.4 Million in Private Placement
7. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
8. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
9. Yongye Biotechnology Announces Record Third Quarter Results
10. Yongye Biotechnology to Present at Roth Conference
11. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015  ATCC, the premier global ... it has been selected by The Michael J. Fox ... lines to academic, pharmaceutical, and biotechnology organizations committed to ... the United States , and more than ... the United States , and more than ...
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... 8, 2015  Today, DuPont and Caribou Biosciences, ... editing, jointly announced a strategic alliance. As part ... respective patent portfolios, with DuPont receiving exclusive intellectual ... row crops, and non-exclusive rights in other agricultural ... --> --> In addition, the ...
(Date:10/8/2015)... Oct. 8, 2015  Today the Wyss Institute for ... of its start-up company Opsonix Inc. The ... Harvard,s Office of Technology Development (OTD) and Opsonix ... therapy for clinical use. --> ... a million people every year in the U.S. — ...
Breaking Biology Technology:
... Amnis Corporation announced today a,major new release ... 3.0 incorporates greatly expanded analytical capabilities,while maintaining an ... provides the user with dozens of new image ... analysis. The new software also provides the user ...
... 10 Cryo-Cell,International, Inc. (OTC Bulletin Board: CCEL) ... established family cord blood banks, today,announced results for ... Consolidated revenues for the first quarter were approximately ... $4.2,million for the first quarter of 2007. The ...
... April 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... studies,of PX-478, pharmacodynamic studies of PX-12 and preclinical ... Meeting of the American Association,for Cancer Research (AACR) ... is currently conducting a Phase 1 clinical trial ...
Cached Biology Technology:
(Date:9/28/2015)...  The monitoring of vital signs, such as ... an essential component of patient assessment. Changes in ... a patient,s condition. However, in general care areas ... during routine observation rounds only once every four ... these observation rounds, the warning signs can go ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced that Lenovo has selected Synaptics , ... FS4202, for its latest smartphone, the Vibe P1. The ... to unlock the device and provide swift access to ... The feature-rich Natural ID FS4202 sensor solution utilizes AES256-bit ...
(Date:9/24/2015)... 2015 Publiceringsförbud fram ... Kerv ( ), det ... världens första kontaktlösa betalningsring på i ... GBP för massproduktion via crowdfunding.  ... Kerv-bärare kan göra direkta kontaktlösa ...
Breaking Biology News(10 mins):
... Mass., May 5 Aware, Inc. (Nasdaq: AWRE ... today reported financial results for its first quarter ended March ... were $4.6 million, a decrease of 22% compared to $5.9 ... its net income and basic and diluted net income per ...
... influenza infection severity have been identified from past outbreaks. ... described in the open access journal BMC Microbiology ... Jonathan Allen and Tom Slezak from Lawrence Livermore National ... acid markers from past pandemic flu strains two weeks ...
... Ind. - Researchers at Purdue University have found a ... in searches for specific genes that shed light on ... Andrew DeWoody, a professor of genetics, and postdoctoral ... step called normalization is no longer necessary with recent ...
Cached Biology News:
... 20 Plasma Immunodepletion Kit specifically removes 20 ... plasma or serum in preparation for further ... into the plasma proteome whether you use ... chromatography or go straight to mass spectrometry. ...
... Since OligoEngine introduced the industry's first ... have constantly strived to keep these tools ... research reports in the field of RNAi. ... enhanced, and expanded RNAi design tools, OligoEngine ...
... for enzyme-/substrate-based blotting what intensifying screens do for ... to 10-fold (or one order of magnitude) in ... Enhancer membrane treatment is a simple, 15-minute procedure ... Western blotting protocol. The result is an increase ...
Biology Products: